---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-154927"
form_type: "8-K"
ticker: "ALGS"
cik: "0001799448"
company_name: "Aligos Therapeutics, Inc."
filed_at: "2026-04-14T23:59:59+00:00"
generated_at: "2026-05-15T06:24:43.003638+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aligos: Phase 2 HBV interim – DSMB ups HBeAg- sample size to 100; FDA Fast Track granted

## Summary
- DSMB recommended increasing HBeAg- cohort from 74 to 100 participants to optimize power; futility criteria not met.
- Study drugs well-tolerated; no viral breakthrough; safety data reviewed across all 174 enrolled participants.
- FDA granted Fast Track Designation for pevifoscorvir sodium based on 96-week Phase 1 data.
- Topline data from B-SUPREME study remains on track for 2027; enrollment in HBeAg- cohort expected by H2 2026.
- Aligos remains blinded to participant-level data; 103 enrolled in HBeAg+ cohort (Part 1a).

## SEC filing metadata
- accession: 0001193125-26-154927
- form_type: 8-K
- ticker: ALGS
- cik: 0001799448
- company_name: Aligos Therapeutics, Inc.
- filed_at: 2026-04-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799448/000119312526154927/0001193125-26-154927-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799448/000119312526154927/d107028d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-154927
- JSON: https://secwatch.observer/filing/0001193125-26-154927.json
- Plain text: https://secwatch.observer/filing/0001193125-26-154927.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.